The impact of pemafibrate on hypertriglyceridemia in patients with type 2 diabetes: A prospective cohort study.

The impact of pemafibrate on hypertriglyceridemia in patients with type 2 diabetes: A prospective cohort study. - The impact of pemafibrate on hypertriglyceridemia in patients with type 2 diabetes: A prospective cohort study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037385

Enrollment

300

Registered

2019-07-16

Start date

2019-07-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemi

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with type 2 diabetes and hypertriglyceridemia who are treated in Hokkaido University or cooperated hospitals from June 2019 to March 2020. 2)Patients who are going to be treated with pemafibrate or switched from other fibrates to pemaribrate. 3)Patients who have been treated with fibrate without switching to pemafibrate or taking no medication over a year. 4) over 20 years old 5) Written informed consent

Exclusion criteria

Exclusion criteria: Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Changes of TG and HDL-C before and after administration of pemafibrate	—

Secondary

Measure	Time frame
1)total lipid metabolism (remnant, sd-LDL, etc) 2)Liver function 3)Renal function 4)Body weight, Body mass index, Abdominal circumference 5)Fasting plasma glucose, HbA1c, insulin sensitivity and insulin secretion 6)Blood pressure 7)Adverse event 8)Influencing factors on lipid metabolism, liver/renal function, and glucose metabolism 9)Variation of blood and urinary examination including lipid metabolism, as well as abdominal ultrasound findings between pemafibrate group and control	—

Measure

Time frame

1)total lipid metabolism (remnant, sd-LDL, etc) 2)Liver function 3)Renal function 4)Body weight, Body mass index, Abdominal circumference 5)Fasting plasma glucose, HbA1c, insulin sensitivity and insulin secretion 6)Blood pressure 7)Adverse event 8)Influencing factors on lipid metabolism, liver/renal function, and glucose metabolism 9)Variation of blood and urinary examination including lipid metabolism, as well as abdominal ultrasound findings between pemafibrate group and control

—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Faculty of Medicine and Graduate School of Medicine Division of Diabetes and Obesity

hmiyoshi@med.hokudai.ac.jp011-706-8192

Outcome results